GLP-1 Medications May Benefit Skin Conditions Like Psoriasis and Hidradenitis Suppurativa | Research

The takeaway

A JAAD continuing medical education review explores how GLP-1 receptor agonists' anti-inflammatory mechanisms could benefit dermatological conditions including psoriasis, hidradenitis suppurativa, and wound healing.

Multiple skin conditions may benefit
This JAAD CME review identifies emerging evidence that GLP-1 receptor agonists may improve psoriasis, hidradenitis suppurativa, wound healing, and pain signaling — expanding the therapeutic scope of these widely used metabolic drugs into dermatology.

What the researchers found

This CME review outlines several key points about GLP-1-based therapies and skin health:

- GLP-1 receptors have broad cellular distribution, including in tissues relevant to skin biology

- GLP-1 receptor agonists attenuate pro-inflammatory cytokine signaling while promoting anti-inflammatory pathways

- Emerging evidence supports relevance in dermatology for:

- Improvement in psoriasis

- Improvement in hidradenitis suppurativa (HS)

- Enhanced wound healing

- Modulation of nociceptive (pain) signaling

- Dual GLP-1/GIP receptor agonists (like tirzepatide) may have additional mechanisms beyond single GLP-1 agonists

- The immunomodulatory effects are mechanistically distinct from the metabolic effects

Why it matters

Millions of dermatology patients with psoriasis and hidradenitis suppurativa need better treatment options. Many of these patients also have metabolic comorbidities like obesity and type 2 diabetes. If GLP-1 medications can simultaneously address metabolic disease and inflammatory skin conditions, they could transform the treatment approach for patients with overlapping conditions — treating the whole patient rather than individual diseases in isolation.

How the study worked

This is a narrative review and CME article published in the Journal of the American Academy of Dermatology. It synthesizes the historical development, mechanisms of action, and emerging dermatological evidence for GLP-1 receptor agonists and dual GLP-1/GIP agonists.

What this study cannot tell us

As a review article, this paper synthesizes emerging evidence without presenting new data. The dermatological evidence for GLP-1 RAs is still early-stage, consisting largely of case reports, small series, and observational data rather than randomized controlled trials. The mechanisms linking GLP-1 receptor activation to skin health are not fully elucidated. Weight loss itself could explain some skin improvements in psoriasis and HS, making it difficult to separate direct skin effects from indirect metabolic benefits.

How to read the evidence

This is a narrative review and continuing medical education article from a top-tier dermatology journal. While it provides an authoritative overview of mechanisms and emerging evidence, it does not present new data or follow systematic review methodology. The dermatological evidence it summarizes is largely early-stage.

When this study was published

Published in 2026, this is an extremely current review that captures the latest thinking on GLP-1 medications' dermatological potential, published in the most prestigious dermatology journal.

The bigger picture

The therapeutic scope of GLP-1-based agents continues to expand at a remarkable pace — from diabetes to obesity, cardiovascular protection, kidney disease, liver disease, neurodegeneration, and now dermatology. This JAAD review signals that the dermatology field is taking seriously the potential of these medications for inflammatory skin diseases. As more patients take GLP-1 drugs for metabolic indications, observational data on skin outcomes will accumulate, potentially accelerating the path to formal dermatological indications.

Questions still open

Would randomized controlled trials of GLP-1 RAs specifically for psoriasis or hidradenitis suppurativa show clinically meaningful improvement?
Are the dermatological benefits of GLP-1 RAs primarily due to weight loss, systemic anti-inflammatory effects, or direct skin-level receptor activation?
Could topical formulations of GLP-1 agonists be developed for wound healing or inflammatory skin conditions?

Common questions

Can Ozempic or Wegovy help with skin conditions?

Emerging evidence suggests they might. This review from the top dermatology journal (JAAD) reports that GLP-1 medications have anti-inflammatory effects that could benefit skin conditions like psoriasis and hidradenitis suppurativa. Some patients have reported skin improvements while taking these drugs for diabetes or weight loss. However, no GLP-1 medication is currently approved for any skin condition, and more research — particularly randomized clinical trials — is needed before they could be recommended specifically for dermatological use.

How could a diabetes drug help with skin inflammation?

GLP-1 receptors are found not just in the pancreas and gut, but in many tissues throughout the body, including immune cells and skin. When GLP-1 medications activate these receptors, they reduce pro-inflammatory signaling (the chemical messages that drive inflammation) and boost anti-inflammatory pathways. Since psoriasis, hidradenitis suppurativa, and many other skin conditions are driven by excessive inflammation, this systemic calming effect could translate to skin improvement.

Read the original research

JAAD CME Part 1: Mechanism of Action of GLP-1 Receptor Agonists and Potential Pathways in Skin Health.

Journal of the American Academy of Dermatology

View on PubMed ↗Publisher’s paper ↗

Citation

Narla, Shanthi; Narla, Radhika R; Corbett, John A. (2026). JAAD CME Part 1: Mechanism of Action of GLP-1 Receptor Agonists and Potential Pathways in Skin Health.. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.01.088